Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (201-210 of 218) with videos related to

Pageof 22
Sort By:
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effectsCarolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2025
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell CarcinomaJeremy Mo, Anne Zaremba, Andrisha-Jade Inderjeeth, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2021
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysisJudith M Versluis, Anne M Hendriks, Alison M Weppler, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
Frontiers in Oncology|November 8, 2021
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter AnalysisAnne Zaremba, Rafaela Kramer, Viola De Temple, et al.
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2021
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionSarah Knispel, Maximilian Gassenmaier, Alexander M Menzies, et al.
Pageof 22

Showing results (201-210 of 218) with videos related to

Sort By:
Pageof 22
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effectsCarolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2025
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell CarcinomaJeremy Mo, Anne Zaremba, Andrisha-Jade Inderjeeth, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2021
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysisJudith M Versluis, Anne M Hendriks, Alison M Weppler, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
Frontiers in Oncology|November 8, 2021
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter AnalysisAnne Zaremba, Rafaela Kramer, Viola De Temple, et al.
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2021
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionSarah Knispel, Maximilian Gassenmaier, Alexander M Menzies, et al.
Pageof 22